GRADE随机对照试验中,2型糖尿病患者体重增加与血糖恶化及心血管和肾脏结局相关,且不依赖于降糖药物种类
GRADE随机试验比较二甲双胍基础上加用甘精胰岛素、格列美脲、利拉鲁肽或西格列汀治疗2型糖尿病。第一年利拉鲁肽和西格列汀组体重下降,甘精胰岛素和格列美脲组体重轻度增加,此后所有组体重均下降。体重增加与血糖恶化及心血管和肾脏结局风险增加相关,且 largely 不依赖于治疗。
要点
- 第一年体重变化:利拉鲁肽-3.5 kg,西格列汀-1.07 kg,甘精胰岛素0.45 kg,格列美脲0.89 kg(P<0.0001)。
- 6个月内体重增加与HbA1c>7.5%风险增加及后续心血管疾病相关(HR 1.03 [95%CI 1.005, 1.06])。
- 1年时体重增加与HbA1c>7.5%(HR 1.05 [1.04, 1.07])和肾脏疾病(HR 1.03 [1.01, 1.06])风险增加相关。
核心结论
- 利拉鲁肽和西格列汀与初始体重下降相关,甘精胰岛素和格列美脲与轻度体重增加相关,随后在二甲双胍治疗的2型糖尿病患者中体重均下降。
- 体重增加与血糖恶化及心血管和肾脏结局风险增加相关,且 largely 不依赖于治疗。
研究设计与样本
- GRADE随机对照试验比较二甲双胍基础上加用甘精胰岛素、格列美脲、利拉鲁肽或西格列汀治疗2型糖尿病,评估5年体重变化及体重增加对结局的影响。
- 参与者n=4,980,年龄57±10岁,44%为非白人,HbA1c 7.5%±0.5%,BMI 34.3±6.8 kg/m2。
主要发现
- 第一年体重变化(均值,95%CI):利拉鲁肽-3.5 kg(-3.8,-3.2),西格列汀-1.07 kg(-1.4,-0.78),甘精胰岛素0.45 kg(0.16,0.74),格列美脲0.89 kg(0.60,1.2)(P<0.0001)。
- 此后所有组体重均下降。
- 6个月内体重增加与HbA1c>7.5%风险增加相关,治疗间差异 modest,并与后续心血管疾病相关(HR 1.03 [95%CI 1.005, 1.06])。
- 1年时体重增加与HbA1c>7.5%(HR 1.05 [1.04, 1.07])和肾脏疾病(HR 1.03 [1.01, 1.06])风险增加相关。
- 基线体重而非体重增加与新发神经病变相关;体重增加与糖尿病治疗满意度降低相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Weight gain with glucose-lowering medications may interfere with effective type 2 diabetes (T2D) management. We evaluated weight change and the effect of weight gain on outcomes over 5 years on four diabetes medications. RESEARCH DESIGN AND METHODS: The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) randomized trial compared the addition of insulin glargine, glimepiride, liraglutide, or sitagliptin to metformin in participants with T2D. We report weight change and hazard ratio (HR) per kilogram of weight change for HbA1c >7.5%; cardiovascular disease (CVD), kidney disease, and neuropathy outcomes; and diabetes treatment satisfaction. RESULTS: Participants (n = 4,980) were 57 ± 10 years, 44% non-White, with HbA1c 7.5% ± 0.5%, and BMI 34.3 ± 6.8 kg/m2. Mean (95% CI) weight change (kg) during the first year was -3.5 (-3.8,-3.2) with liraglutide,-1.07 (-1.4,-0.78) with sitagliptin, 0.45 (0.16, 0.74) with glargine, and 0.89 (0.60, 1.2) with glimepiride (P < 0.0001). Thereafter, weight decreased in all groups. Weight gain within the first 6 months was associated with increased risk of HbA1c >7.5%, with modest differences by treatment, and with subsequent CVD (HR 1.03 [95% CI 1.005, 1.06]). Weight gain at 1 year was associated with increased risk of HbA1c >7.5% (HR 1.05 [1.04, 1.07]) and kidney disease (HR 1.03 [1.01, 1.06]). Baseline weight, but not weight gain, was associated with new-onset neuropathy. Weight gain was associated with lower diabetes treatment satisfaction. CONCLUSIONS: Liraglutide and sitagliptin were associated with initial weight loss and glargine and glimepiride with slight weight gain, followed by weight loss in metformin-treated T2D. Weight gain was associated with worsening glycemia and increased risk of cardiovascular and kidney outcomes largely independent of treatment.
引用
- Wexler DJ, Garvey WT, Ghosh A, et al. Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial. Diabetes Care. 2025. PMID: 40267365. doi:10.2337/dc24-2825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。